Wiggin and Dana LLP represented BioInvent International AB on the license agreement with Exelixis, Inc. to develop novel antibody-based immuno-oncology therapies. The collaboration is intended to […]
BioInvent’s Licensing Agreement with Exelixis
Rallybio’s Acquisition of Worldwide License Rights to KY 1066
Wiggin and Dana represented Rallybio Corporation on the acquisition. Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming […]
Affibody AB’s License and Collaboration Agreement with ACELYRIN, INC.
Wiggin and Dana represented Affibody AB on the deal. Affibody AB signed a partnership agreement with ACELYRIN, INC. to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A […]
Notable Labs, Inc.’s Acquisition of Development and Commercialization Rights to Volasertib
Wiggin and Dana represented Notable Labs, Inc. on the transaction. Notable Labs, Inc.), a pioneer and developer of predictive precision medicines, has obtained worldwide rights to […]